Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 1, 2026, 2:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Dimethyltryptamine (DMT) Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics, Safety, and Tolerability of Intramuscular 5-MeO-DMT in Healthy Volunteers

NCT05698095
View directory record Official record
Conditions
Pharmacokinetics, Safety, Tolerability
Interventions
5-methoxy-N,N-dimethyltryptamine succinate salt, Placebo
Drug
Lead sponsor
Usona Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Nov 29, 2023 · Synced Sep 1, 2026, 2:52 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Psilocybin Therapy for Chronic Low Back Pain

NCT05351541
View directory record Official record
Conditions
Chronic Low-back Pain
Interventions
Psilocybin therapy with Zolpidem and Modafinil, Psilocybin therapy with Zolpidem, Psilocybin therapy with Modafinil, Psilocybin therapy with Placebo
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
25 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Early Phase 1 Interventional Results available

Psilocybin Cancer Anxiety Study

NCT00957359
View directory record Official record
Conditions
Cancer
Interventions
Psilocybin, Niacin
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years to 76 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT02145091
View directory record Official record
Conditions
Healthy
Interventions
Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 1, 2026, 2:52 PM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use Disorder

NCT04620759
View directory record Official record
Conditions
Major Depressive Disorder, Alcohol Use Disorder
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Withdrawn Phase 2 Interventional

Trifecta Research Study

NCT06810765
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Trauma, Brain Injuries
Interventions
Hormone Replacement Therapy (HRT), Magnetic Resonance Therapy (MeRT), ibogaine with magnesium treatment, 5-MeO-DMT
Other · Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Active, not recruiting Phase 2 Interventional

Psilocybin Therapy for Depression in Bipolar II Disorder

NCT05065294
View directory record Official record
Conditions
Bipolar II Disorder
Interventions
Psilocybin therapy
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 70 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 1, 2026, 2:52 PM EDT
Recruiting Phase 1 Interventional

The Potential Therapeutic Effects of Psychedelic, N, N-dimethyltryptamine (DMT), on Alcohol Use Disorder (AUD)

NCT06070649
View directory record Official record
Conditions
Alcohol Use Disorder (AUD), Alcohol-Related Disorders, Alcohol Use
Interventions
0.3mg/kg/min Dimethyltryptamine + Normal Saline infusion, 0.2 mg/kg/min + Dimethyltryptamine 0.01mg/kg/min infusion, 25 mg Diphenhydramine (5 min) + Normal Saline
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 1Phase 2 Interventional

Effects of Psilocybin in Advanced-Stage Cancer Patients With Anxiety

NCT00302744
View directory record Official record
Conditions
Anxiety
Interventions
Psilocybin (drug), Niacin, MRI
Drug · Other · Diagnostic Test
Lead sponsor
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated Mar 12, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

A Study of a N, N-dimethyltryptamine (DMT) Analog (CYB004) in Participants With Generalized Anxiety Disorder (GAD)

NCT06051721
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
CYB004, Psychotherapy
Drug · Behavioral
Lead sponsor
Cybin IRL Limited
Industry
Eligibility
18 Years to 65 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
6
States / cities
Hollywood, Florida • Miami Lakes, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Recruiting Phase 2 Interventional

Psilocybin Therapy for Depression in Parkinson's Disease

NCT06455293
View directory record Official record
Conditions
Parkinson Disease, Depression
Interventions
Psilocybin, Pimavanserin
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

Fixed Order, Open-Label, Dose-Escalation Study of DMT in Humans

NCT04711915
View directory record Official record
Conditions
Major Depressive Disorder, Depression
Interventions
0.1 mg/kg Dimethyltryptamine (DMT), 0.3 mg/kg Dimethyltryptamine (DMT)
Drug
Lead sponsor
Yale University
Other
Eligibility
21 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 1 Interventional Results available

Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors

NCT02950467
View directory record Official record
Conditions
Distress, Depression, Grief
Interventions
Psilocybin, Modified brief Supportive Expressive Group Therapy
Drug · Behavioral
Lead sponsor
Joshua Woolley
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jan 6, 2021 · Synced Sep 1, 2026, 2:52 PM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Open-Label Dose-Ranging Study of Oral SM-001 in Healthy Adults

NCT05894902
View directory record Official record
Conditions
Major Depression, Post Traumatic Stress Disorder
Interventions
SM-001
Drug
Lead sponsor
Advanced Integrative Medical Science Institute
Other
Eligibility
25 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 6, 2023 · Synced Sep 1, 2026, 2:52 PM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

Effects of Psilocybin on Electrophysiology and the Dynamic Content of Thought

NCT05301608
View directory record Official record
Conditions
Healthy
Interventions
Psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Psilocybin-facilitated Smoking Cessation Treatment: A Pilot Study

NCT01943994
View directory record Official record
Conditions
Nicotine Dependence
Interventions
Psilocybin-assisted treatment, Nicotine Replacement Therapy (NRT)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 65 Years
Enrollment
82 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2023
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 1, 2026, 2:52 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics and Safety of GH001 Delivered Via a GH001 Aerosol Delivery System in Healthy Subjects

NCT07540494
View directory record Official record
Conditions
Healthy Adult
Interventions
5 Methoxy N,N Dimethyltryptamine, GH001 Aerosol Delivery System
Drug · Device
Lead sponsor
GH Research Ireland Limited
Industry
Eligibility
21 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 19, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Neural Effects of Intravenous N,N-dimethyltryptamine (DMT)

NCT07693257
View directory record Official record
Conditions
Healthy Participants Study
Interventions
N,N-Dimethyltryptamine (15 mg), N,N-Dimethyltryptamine (17.5 mg)
Drug
Lead sponsor
Jon Dean
Other
Eligibility
18 Years to 65 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional

Psilocybin Therapy for Depression and Anxiety in Parkinson's Disease

NCT04932434
View directory record Official record
Conditions
Parkinson Disease, Depression, Anxiety
Interventions
Psilocybin therapy
Drug
Lead sponsor
Joshua Woolley, MD, PhD
Other
Eligibility
40 Years to 75 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Sep 1, 2026, 2:52 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Investigation of Psychedelic Effects in Psychoactive Substances

NCT06772753
View directory record Official record
Conditions
Psychedelic Effects in Healthy Volunteers
Interventions
Placebo, Psilocybin, Ketamine, Dextromethorphan (DXM), Dimethyltryptamine (DMT), Methylenedioxymethamphetamine (MDMA), Tetrahydrocannabinol (THC)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 22, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Terminated No phase listed Observational Accepts healthy volunteers

Computer Game, Qualitative, and MEG/EEG Assessment of Serotonergic Psychedelics

NCT06624137
View directory record Official record
Conditions
OCD, Major Depressive Disorder (MDD), Alcohol Use Disorder (AUD), Healthy Volunteer, Migraine, PTSD, PTSD - Post Traumatic Stress Disorder, Addiction, Tobacco Use Disorder, Obsessive Compulsive Disorder (OCD), Opioid Use Disorder
Interventions
Serotonergic Psychedelic, Placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
2
States / cities
Hamden, Connecticut • West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Completed Phase 2 Interventional Results available

Psychopharmacology of Psilocybin in Cancer Patients

NCT00465595
View directory record Official record
Conditions
Depressive Symptoms, Anxiety, Cancer
Interventions
psilocybin
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
21 Years to 80 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 18, 2018 · Synced Sep 1, 2026, 2:52 PM EDT
Recruiting Phase 2 Interventional

The Efficacy of Psilocybin Therapy for Depression in Parkinson's Disease

NCT07610369
View directory record Official record
Conditions
Depression, Parkinson's Disease (PD)
Interventions
Psilocybin (drug)
Drug
Lead sponsor
Yale University
Other
Eligibility
40 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 19, 2026 · Synced Sep 1, 2026, 2:52 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Trifecta Research Study

NCT07717866
View directory record Official record
Conditions
PTSD - Post Traumatic Stress Disorder, Cognitive Dysfunction, Brain Injury, Depression - Major Depressive Disorder, Suicidal Ideation
Interventions
Magnetic e-Resonance Therapy (MeRT), Ibogaine Hydrochloride with Magnesium Sulfate, 5-methoxy-N,N-dimethyltryptamine, Physiological Supplementation
Device · Drug
Lead sponsor
Axial Therapeutic Research
Industry
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Sep 1, 2026, 2:52 PM EDT